SCHEMBL23801142

SCHEMBL23801142

O=C(O)CN1C(=O)CCc2ccc(Br)cc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.49
MAPK9 P45984 1/20 0.49
MAPK10 P53779 1/20 0.49
HDAC1 Q13547 3/20 0.47
HDAC6 Q9UBN7 3/20 0.47
HDAC8 Q9BY41 1/20 0.47
ALDH1A1 P00352 4/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 2/20 0.45
ALOX12 P18054 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
LMNA P02545 1/20 0.41
PMP22 Q01453 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GFER P55789 1/20 0.41
HSD17B3 P37058 3/20 0.41
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10508437 0.82 CHRM1 (0.48) HDAC1HDAC6HDAC8ALDH1A1MEN1
SCHEMBL10509893 0.82 PTGDR2 (0.48) HDAC1HDAC6HDAC8MEN1KMT2A
SCHEMBL12569515 0.82 TSHR (0.59) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL23320864 0.80 MAPT (0.44) MAPK8MAPK9MAPK10HDAC1HDAC6
SCHEMBL12546130 0.79 XIAP (0.42) ALDH1A1MAPTMEN1KMT2ATSHR
SCHEMBL29456062 0.78 POLB (0.64) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL933584 0.78 POLB (0.64) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL1907059 0.78 HDAC1 (0.45) HDAC1HDAC6HDAC8ALDH1A1GAA
SCHEMBL25036443 0.77 HDAC6 (0.51) MAPK8MAPK9MAPK10HDAC1HDAC6
SCHEMBL2955428 0.76 MEN1 (0.43) HDAC1HDAC6HDAC8ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB MAPK8 1742/4885MAPK9 1534/4885MAPK10 1397/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB MAPK8 1788/4885MAPK9 1635/4885MAPK10 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.